Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Amyloid Fibrils03:03

Amyloid Fibrils

9.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Polycatechols Inhibit Ferroptosis And Modulate Tau Liquid-liquid Phase Separation To Mitigate Alzheimer's Disease.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Polycatechols Inhibit Ferroptosis And Modulate Tau Liquid-liquid Phase Separation To Mitigate Alzheimer's Disease.

Related Experiment Video

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K

Polycatechols inhibit ferroptosis and modulate tau liquid-liquid phase separation to mitigate Alzheimer's disease.

Hariharan Moorthy1, Madhu Ramesh1, Dikshaa Padhi1

  • 1Bioorganic Chemistry Laboratory, New Chemistry Unit and School of Advanced Materials, Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru, Karnataka 560064, India. tgraju@jncasr.ac.in.

Materials Horizons
|April 22, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

New polycatechol agents, PDP and PLDP, combat Alzheimer's by inhibiting ferroptosis and amyloid toxicity. PLDP uniquely modulates tau liquid-liquid phase separation, offering a novel therapeutic strategy for neurodegenerative diseases.

More Related Videos

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.9K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

Related Experiment Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

11.9K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Polymer Science

Background:

  • Alzheimer's disease (AD) involves complex neurodegeneration affecting cognition.
  • Current treatments for amyloid-β (Aβ) and tau pathologies show limited efficacy.
  • Ferroptosis and tau liquid-liquid phase separation (LLPS) are emerging mechanisms in AD pathogenesis.

Purpose of the Study:

  • To investigate polycatechols (PDP, PLDP) as multifunctional agents against AD.
  • To explore their potential in modulating the interplay between ferroptosis and amyloid toxicity.
  • To assess their impact on tau LLPS and aggregate formation.

Main Methods:

  • Synthesis and characterization of polycatechols (PDP, PLDP).
  • In vitro assays for labile iron pool (LIP) sequestration, Aβ and tau aggregation inhibition.
  • Free radical scavenging and mitochondrial protection assays.
  • Assessment of ferroptosis inhibition and neuronal cell death rescue.
  • Analysis of PLDP's effect on tau LLPS and aggregate modulation.

    • Main Results:

    • Polycatechols sequester LIP, inhibit Aβ and tau aggregation, scavenge radicals, and protect mitochondria.
    • PDP and PLDP effectively prevent ferroptosis and rescue neuronal cells from death.
    • PLDP uniquely promotes tau LLPS while inhibiting toxic aggregate formation.
    • This represents a novel polymer-based strategy integrating ferroptosis inhibition and amyloid toxicity counteraction.

    Conclusions:

    • Polycatechols demonstrate significant potential as multifunctional therapeutic agents for Alzheimer's disease.
    • The dual action against ferroptosis and amyloid pathology, coupled with tau LLPS modulation, offers a comprehensive approach.
    • PLDP's unique mechanism provides a novel strategy for targeting tauopathies within the broader context of AD.